Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and …
$0.22+0.82%
报价 2026-11-06
市值
$3.4M
EV
$5.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -92.1%
$0.22$2.82
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TRAWOnconova Therapeutics, Inc. | $3.4M | +0.8% | -89.3% | 0% | – | – | – | |
| CINGCingulate Inc. | $61.9M | +0.5% | -87.1% | 0% | – | – | – | |
| DWTXDogwood Therapeutics, Inc. | $48.9M | +23.1% | +114891.6% | -4.8% | – | – | – | |
| COCPCocrystal Pharma, Inc. | $20M | +4.0% | -100.0% | 0% | – | – | – | |
| BOLTBolt Biotherapeutics, Inc. | $12.6M | +2.5% | -66.1% | 95.7% | – | – | – | |
| IMRNImmuron Limited | $5.4M | -2.2% | – | 64.5% | – | – | – | |
| IMNNImunon, Inc. | $4.7M | -6.2% | -62.5% | 0% | – | – | – | |
| MBIOMustang Bio, Inc. | $2.7M | +0.2% | +10900.0% | 0% | – | – | – | |
| EVGNEvogene Ltd. | $2.3M | -17.8% | – | 30.9% | – | – | – | |
| 同行中位数 | – | – | -64.3% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。